Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Donepezil Hydrochloride Clear all
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study With Aricept® (Donepezil)

NCT01042314
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)

NCT03438604
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Donepezil in Preventing Delirium in Hospitalized Elderly

NCT00182884
View directory record Official record
Conditions
Postoperative Complications, Delirium
Interventions
Donepezil
Drug
Lead sponsor
Indiana University Health
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Oct 4, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional

A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil

NCT00672945
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PRX-03140, Placebo
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • National City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

NCT00478205
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 4, 2026, 5:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

NCT01194336
View directory record Official record
Conditions
Biomarkers, Pharmacological
Interventions
Huperzine A, Donepezil, Galantamine, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 4, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 4, 2026, 5:48 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 4 Interventional

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 4, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
23
States / cities
Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Results available

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

NCT04308304
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1942, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Idalopirdine 60 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
1,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

NCT02055703
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, itraconazole, rifampin, digoxin, donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil

NCT01406145
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ASP0777, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
San Diego, California • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

NCT02087865
View directory record Official record
Conditions
Genetic Risk for Alzheimer's Disease
Interventions
donepezil HCL, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

NCT00916383
View directory record Official record
Conditions
Irritation/Irritant
Interventions
350 mg Donepezil Transdermal Patch, Placebo Patch
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Phoenix, Arizona • Fresno, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SUVN-502, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02337907
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, BI 409306, Donepezil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 4, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

NCT00842816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ST101, Placebo
Drug
Lead sponsor
Sonexa Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 4, 2026, 5:48 AM EDT